Key result
The abstract does not report quantitative results for the safety and feasibility of percutaneous mitral balloon valvuloplasty in mitral stenosis patients with moderate mitral regurgitation.
Why the study?
PMBV is established for symptomatic moderate or severe rheumatic mitral valve disease, but is not preferred in MS with moderate MR due to the risk of severe MR.
Does percutaneous mitral balloon valvuloplasty have acceptable safety and feasibility in symptomatic mitral stenosis patients with moderate mitral regurgitation compared to those with mild or no mitral regurgitation?
Population
Symptomatic MS patients with moderate MR vs mild or no MR
Comparison
MS patients with moderate MR vs MS patients with mild or no MR undergoing PMBV
Design
Single-center study
Authors
Loading...
PMBV appears comparably safe in selected MS patients with moderate MR; leaves open whether it warrants broader use pending larger trials.
Observational
No
Does percutaneous mitral balloon valvuloplasty have acceptable safety and feasibility in symptomatic mitral stenosis patients with moderate mitral regurgitation compared to those with mild or no mitral regurgitation?
Çelik et al. (2020) conducted an observational in Symptomatic mitral stenosis. Percutaneous mitral balloon valvuloplasty vs. Mitral stenosis patients with mild or no mitral regurgitation was evaluated on Safety and feasibility (post-procedural parameters). The abstract does not report quantitative results for the safety and feasibility of percutaneous mitral balloon valvuloplasty in mitral stenosis patients with moderate mitral regurgitation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: